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Introduction
The conserved kinase Aurora B is an important regulator of   
mitotic cell division (Carmena et al., 2009). Aurora B forms the 
catalytic core of the chromosomal passenger complex (CPC), 
which includes the regulatory proteins INCENP, Survivin, and 
Borealin (Carmena et al., 2009). The CPC associates with the 
centromere from prophase until metaphase and transfers to the 
spindle midzone in anaphase and the midbody in late cyto­
kinesis, and Aurora B localization requires all three regulatory 
subunits of the CPC (Carvalho et al., 2003; Honda et al., 2003; 
Jeyaprakash et al., 2007). Furthermore, Survivin directly inter­
acts with Aurora B and the N terminus of INCENP and medi­
ates targeting of the CPC to chromosomes (Wheatley et al., 
2001; Vader et al., 2006; Kelly et al., 2010).
Aurora  B  has  a  well­established  function  in  promot­
ing  release  of  misattached  kinetochore  microtubules  until   
bipolar attachment is achieved (Tanaka et al., 2002; Liu et al., 
2009). Furthermore, Aurora B is required for cleavage furrow 
ingression (Fuller et al., 2008), and impaired Aurora B activ­
ity correlates with chromosome misalignment in metaphase, 
missegregated chromosomes during anaphase, and failure of 
cytokinesis (Adams et al., 2001; Ditchfield et al., 2003).
Aurora B is also involved in the spindle checkpoint, a 
surveillance mechanism that delays anaphase until all chro­
mosomes are correctly bioriented; however, its precise role is 
a matter of active investigation (Nezi and Musacchio, 2009). 
In budding yeast, Ipl1/Aurora is required for spindle check­
point function in response to a lack of tension across attached 
kinetochores (Biggins and Murray, 2001; Cheeseman et al., 
2002). In higher eukaryotic cells, catalytic activity of Aurora B 
is required for recruitment of checkpoint protein BubR1 to 
kinetochores and sustained mitotic arrest in the absence of 
tension (Ditchfield et al., 2003; Lampson and Kapoor, 2004). 
Furthermore,  recent  studies  in  yeast  (Pinsky  et  al.,  2009; 
Vanoosthuyse  and  Hardwick,  2009)  and  vertebrate  cells 
(Maldonado and Kapoor, 2011; Santaguida et al., 2011; Saurin 
et al., 2011) have shown that potent inhibition of Aurora B   
activity weakens the mitotic arrest in the presence of many 
unattached kinetochores.
Aurora B is associated with INCENP throughout the cell 
cycle;  however,  Aurora  B  kinase  activity  peaks  in  mitosis 
(Bolton et al., 2002). Activation of Aurora B occurs through a 
two­step mechanism: in the first step, Aurora B binds to the   
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urora B kinase activity is required for successful 
cell division. In this paper, we show that Aurora B 
is phosphorylated at serine 331 (Ser331) dur-
ing mitosis and that phosphorylated Aurora B localizes to 
kinetochores in prometaphase cells. Chk1 kinase is essen-
tial for Ser331 phosphorylation during unperturbed pro-
metaphase or during spindle disruption by taxol but not 
nocodazole. Phosphorylation at Ser331 is required for 
optimal phosphorylation of INCENP at TSS residues, for 
Survivin  association  with  the  chromosomal  passenger 
complex, and for complete Aurora B activation, but it is 
dispensable for Aurora B localization to centromeres, for 
autophosphorylation at threonine 232, and for associa-
tion with INCENP. Overexpression of Aurora B
S331A, in 
which Ser331 is mutated to alanine, results in spontane-
ous chromosome missegregation, cell multinucleation,   
unstable binding of BubR1 to kinetochores, and impaired 
mitotic delay in the presence of taxol. We propose that 
Chk1 phosphorylates Aurora B at Ser331 to fully induce 
Aurora B kinase activity. These results indicate that phos-
phorylation at Ser331 is an essential mechanism for   
Aurora B activation.
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Figure 1.  Chk1 phosphorylates Aurora B at Ser331. (A) Chk1 in vitro kinase assay. (top) Autoradiography analysis (
32P) of phosphorylated (phospho)   
Aurora B
KD. (bottom) Western blot (WB) analysis of total Aurora B
KD. (B) Mapping the Chk1 phosphorylation site. (top) Amino acids inclusive and surrounding 
Ser331 (S
331) showing N terminal trypsin and glutamyl endopeptidase cleavage sites. (bottom left) HPLC analysis of radiolabeled Aurora B
KD after diges-
tion with trypsin. The main radioactive fraction is indicated by an arrowhead. (bottom right) Edman degradation analysis of the phosphopeptide from 
the main radioactive fraction. The graph shows radioactivity released from the membrane. (C) Chk1 in vitro kinase assay using purified proteins Aurora B
WT  451 Chk1 phosphorylates Aurora B at serine 331 • Petsalaki et al.
(wild type [WT]), Aurora B
S331A (S331A), or Aurora B
T179A (T179A) as substrates. (top) Autoradiography analysis. (bottom) Western blot analysis of the reac-
tions. (D) Densitometric analysis of Chk1 in vitro kinase assay from C. Radioactive labeling of the wild-type protein was plotted as 100%. Error bars show 
the standard deviation from the mean from three independent experiments. (E) Alignment of Aurora B and human Aurora C (h AurC) protein sequences. 
Ser331 is marked by asterisk. (F) View of Xenopus Aurora B–INCENP
790–847 (blue and magenta ribbons, respectively) in complex with hesperadine (ball 
and stick model). Ser
347 of Xenopus Aurora B (equivalent of human Ser331) is circled and indicated by an arrow. (G) Chk1 in vitro kinase assay. Western 
blot analysis of phosphorylated (pS331) and total Aurora B
KD using the anti-pS331 antiserum. -PPase,  protein phosphatase; pep S331, unphosphory-
lated Ser331 synthetic peptide; pep pS331, phospho-S331 synthetic peptide.
 
C­terminal IN box sequence of INCENP spanning amino acids 
822–900 (human numbering) and is autophosphorylated at thre­
onine 232 (Thr232) within its activation loop (Honda et al., 2003; 
Yasui et al., 2004). This step represents an intermediate state of 
Aurora B activation in which the Aurora B C­terminal tail sta­
bilizes an open conformation of the catalytic cleft (Sessa et al., 
2005). In the second step, Aurora B phosphorylates INCENP in 
trans at two adjacent serine residues of the conserved TSS se­
quence (Bishop and Schumacher, 2002; Honda et al., 2003). 
Phosphorylation of the TSS motif and release of the Aurora B 
C­terminal tail through an undescribed mechanism generate the 
fully active kinase (Sessa et al., 2005). TD­60, microtubules, 
and priming phosphorylation of Aurora B substrates by Plk1 
and haspin catalyze the first step of Aurora B activation in vitro 
(Rosasco­Nitcher et al., 2008). Furthermore, local clustering 
at chromosomes stimulates Aurora B autoactivation, and Mps1   
kinase phosphorylates Borealin to enhance Aurora B activity by an 
unknown mechanism (Kelly et al., 2007; Jelluma et al., 2008).
Chk1 kinase is a well­established component in the DNA 
damage and DNA replication checkpoints (Smith et al., 2010). 
Furthermore, Chk1 protects cells against spontaneous chromo­
some missegregation and is required for sustained mitotic arrest 
in the presence of taxol, a drug that dampens microtubule dynam­
ics and primarily interferes with kinetochore tension but not 
when microtubules are completely depolymerized by nocodazole   
(Zachos et al., 2007; Peddibhotla et al., 2009). Spindle check­
point failure in Chk1­deficient cells is associated with impaired 
localization of BubR1 to kinetochores and reduced Aurora B   
kinase activity. However, the mechanism of Aurora B regulation 
by Chk1 has not been previously described (Zachos et al., 2007).
In the present study, we identify the conserved residue 
serine 331 (Ser331) of human Aurora B as the Chk1 phosphory­
lation site in vitro and, using a phosphospecific antibody raised 
against this site, we show that Chk1 is required for Ser331 phos­
phorylation during unperturbed prometaphase or spindle dis­
ruption by taxol but not during prophase, cytokinesis, or treatment 
of cells with nocodazole. Furthermore, using cells overexpressing 
wild­type or nonphosphorylatable S331A mutant Aurora B, we 
propose that Ser331 phosphorylation is required for optimal phos­
phorylation of INCENP at the TSS motif, Survivin association 
with the CPC, and complete Aurora B activation but not for 
Aurora B localization to centromeres, phosphorylation at Thr232, 
or association with INCENP. In addition, overexpression of S331A 
Aurora B results in spontaneous chromosome missegregation, 
cell multinucleation, defective accumulation of BubR1 at kineto­
chores, and impaired mitotic delay in response to taxol. On the 
basis of these findings, we propose that Ser331 phosphorylation 
by Chk1 is an essential mechanism for Aurora B activation.
Results
Chk1 phosphorylates Aurora B at Ser331 
in vitro
Chk1 phosphorylated kinase­dead human Aurora B (Aurora B
KD) 
in vitro, and this phosphorylation was abolished in the pres­
ence of the selective Chk1 inhibitor UCN­01 (Fig. 1 A). To map 
the Chk1 phosphoacceptor sites, Aurora B
KD was radiolabeled 
by Chk1 and digested with Trypsin, and the resulting pep­
tides were resolved by HPLC (Fig. 1 B). The phosphopeptide 
from the main radioactive fraction was subjected to Edman   
degradation, and radioactivity was released after three cycles   
(Fig. 1 B). This process was repeated after digestion of radio­
labeled Aurora B
KD with glutamyl endopeptidase and resulted 
in a main radioactive fraction that released radioactivity after   
17 cycles (Fig. S1, A and B). Ser331 is the only residue on human 
Aurora B consistent with both phosphorylation patterns. There­
fore, our results suggest Ser331 is the main Chk1 phosphoryla­
tion site in vitro (Fig. 1 B).
To verify this, bacterially expressed wild­type Aurora B 
(Aurora B
WT), Aurora B
S331A harboring a nonphosphorylatable 
mutation of Ser331 to alanine (S331A), or Aurora B
T179A, in 
which threonine 179 was changed to alanine (negative control) 
was used as a substrate in Chk1 in vitro kinase assays. Mutation 
of Ser331 to alanine or inhibition of Chk1 activity by UCN­01 
markedly  reduced  substrate  phosphorylation  compared  with 
Aurora B
WT (Fig. 1, C and D). In comparison, phosphorylation 
of Aurora B
T179A by Chk1 was similar to Aurora B
WT (Fig. 1,   
C and D). These results show that Chk1 phosphorylates human 
Aurora B at Ser331 in vitro.
Multiple sequence alignment demonstrated that Ser331 
is conserved in Aurora B proteins from different species and 
also in human Aurora C, an Aurora paralogue that exhibits 
structural properties similar to Aurora B and can perform re­
lated mitotic functions in the absence of Aurora B (Fig. 1 E; 
Han et al., 2007; Slattery et al., 2009). Ser331 is located at the 
foot of the Aurora B C­terminal tail, which interacts with the 
IN box of INCENP in the partially active complex (Fig. 1 F; 
Sessa et al., 2005).
To  further  investigate  Ser331  phosphorylation,  an   
antiphospho­Ser331 (anti­pS331) antiserum was raised against 
the human protein sequence. As shown in Fig. 1 G, this anti­
serum recognized Aurora B
KD phosphorylated by Chk1 in vitro, 
and  immunoreactivity  was  abolished  after  substrate  treat­
ment with  protein phosphatase (Fig. 1 G, ­PPase) or incuba­
tion of the antiserum with the phosphorylated (Fig. 1 G, pep 
pS331) but not the unphosphorylated (Fig. 1 G, pep S331) syn­
thetic peptides.JCB • VOLUME 195 • NUMBER 3 • 2011   452
Figure 2.  Chk1 is required for Ser331 phosphorylation during unperturbed prometaphase. (A) Ser331 phosphorylation (pS331) in BE cells during unper-
turbed mitosis. (B) Localization of pS331 and Survivin-GFP. (C) BE cells were transfected with negative siRNA (control) and Chk1 siRNA (siChk1) or treated 
with UCN-01 for 16 h. The frequency of cells exhibiting the respective phenotype and mean pS331/CENP-A fluorescence intensity values (boxed numbers) 
are shown. (D) Localization of total Aurora B in BE cells transfected as in C. Insets show magnified kinetochores. Bars, 5 µm.453 Chk1 phosphorylates Aurora B at serine 331 • Petsalaki et al.
Aurora B is phosphorylated at Ser331  
in mitosis
Confocal microscopy analysis of BE human colon carcinoma 
cells  during  unperturbed  prometaphase  showed  that  pS331   
Aurora B was juxtaposed to CENP­A, near kinetochores (Fig. 2 A),   
whereas total Aurora B localized along the extended centro­
mere as previously described (Fig. 2 D; Cooke et al., 1987). 
Importantly, pS331 staining was only detectable in the pres­
ence of the protein phosphatase inhibitor microcystin, thus 
suggesting  that  pS331  is  sensitive  to  phosphatase  activity 
(Gorbsky and Ricketts, 1993). Furthermore, pS331 localized to 
kinetochores during prophase and metaphase, to the midzone 
in anaphase and the midbody in telophase and late cytokine­
sis (Fig. 2 A). In addition, BE cells transiently expressing Sur­
vivin fused to GFP (Survivin­GFP) exhibited pS331 juxtaposed 
to Survivin­GFP, near kinetochores (Fig. 2 B). Depletion of   
Aurora B expression by transient transfection of BE cells with 
Aurora B siRNA (Fig. S1 C, siAurora B) impaired pS331 stain­
ing at prometaphase kinetochores (Fig. S1 D). In some cells, 
pS331 staining was also detectable at centrosomes; however, 
this signal persisted after depletion of Aurora B by siRNA and 
was likely spurious (Fig. S1 E; Posch et al., 2010). Furthermore, 
pS331 kinetochore staining was reduced after incubation of the 
anti­pS331 antiserum with the phosphorylated peptide pS331 
compared with the unphosphorylated peptide S331 synthetic 
peptides (Fig. S1 F). These results show that pS331 localizes 
to kinetochores in unperturbed prometaphase, the midzone in 
anaphase, and the midbody in telophase and cytokinesis.
Chk1 is required for Ser331 
phosphorylation during  
unperturbed prometaphase
To investigate the role of Chk1 for Ser331 phosphorylation,   
BE cells transiently transfected with negative siRNA (control), 
Chk1 siRNA (siChk1), or treated with UCN­01 were analyzed 
by confocal microscopy (Figs. 2 C and S2 A). Depletion of 
Chk1 or inhibition of Chk1 kinase activity by UCN­01 dimin­
ished pS331 staining at prometaphase kinetochores as indicated 
by  reduced  pS331/CENP­A  fluorescence  intensity  compared 
with controls (Fig. 2 C and Tables I and S1). Significantly, im­
paired pS331 staining after Chk1 depletion was not caused 
by reduced levels of Aurora B expression (Fig. S2 B). Further­
more, total Aurora B localized to centromeres in all control 
(22/22) and Chk1­depleted (20/20) cells examined in pro­
metaphase (Fig. 2 D). These results show that Chk1 activity is re­
quired for optimal phosphorylation of Aurora B at Ser331 during 
unperturbed prometaphase. Remarkably, depletion of Chk1 did 
not detectably reduce pS331 staining compared with controls 
in prophase or cytokinesis (Fig. S2, C and D).
Chk1 is required for Ser331 
phosphorylation in the presence of taxol
Treatment with taxol or nocodazole activates the spindle check­
point in checkpoint­proficient cells (Zachos et al., 2007). In the 
presence of taxol, Chk1­depleted BE cells exhibited impaired 
pS331 staining at prometaphase kinetochores compared with 
controls (Fig. 3 A and Table I). In contrast, after treatment with 
nocodazole, Chk1­depleted and control BE cells exhibited 
similar levels of pS331 at kinetochores (Fig. 3 B and Table I). 
Importantly, total Aurora B localized to centromeres in the   
presence of taxol or nocodazole in all control (17/17) and Chk1­ 
depleted (20/20) cells examined in prometaphase (Fig. 3 C). 
Collectively, these results show that Chk1 is required for Ser331 
phosphorylation in the presence of taxol but not nocodazole.
Generation of CHO
WT and CHO
S331A cell lines
To investigate the significance of Ser331 phosphorylation for 
Aurora  B  functions,  CHO  cells  expressing  6×Myc­tagged   
Aurora B
WT (CHO
WT) or Aurora B
S331A (CHO
S331A) under con­
trol of a tetracycline­induced promoter were generated. Addition 
of tetracycline for 8–24 h stimulated accumulation of 6×Myc– 
Aurora B
WT and 6×Myc–Aurora B
S331A at approximate levels   
10­fold higher than the endogenous protein (Figs. 3 D and S2 E). 
This level of expression was selected to disrupt endogenous   
Aurora B functions while maintaining correct localization of wild­
type 6×Myc–Aurora B to centromeres (Ditchfield et al., 2003). 
After  induction  with  tetracycline,  6×Myc–Aurora  B
WT  and 
6×Myc–Aurora B
S331A proteins localized to centromeres during un­
perturbed prometaphase in all (30/30) cells examined (Fig. 3 E). 
Similar results were obtained in the presence of taxol or nocodazole   
(Fig. 3 F) in all (30/30) cells examined. Please note that CENP­B 
localizes to sister kinetochores in CHO cells (Cooke et al., 1990; 
Wordeman and Mitchison, 1995). Furthermore, CHO cells ex­
pressing wild­type, but not the S331A mutant, Aurora B exhibited 
pS331 staining (Figs. 4 A and S2 F), and pS331 was juxtaposed 
to CENP­A–GFP in prometaphase (Fig. 4 A).
Phosphorylation at Ser331 is required for 
optimal Aurora B kinase activity
To investigate the significance of Ser331 phosphorylation for 
Aurora B catalytic activity, CHO
WT or CHO
S331A cells induced 
with tetracycline were treated with taxol or nocodazole, and   
Table I.  pS331 fluorescence intensity values at prometaphase kinetochores
Treatment BE control BE siChk1 P-values
Fluorescence intensity  
(pS331/CENP-A)
n (kinetochore pairs, 
cells)
Fluorescence intensity  
(pS331/CENP-A)
n (kinetochore pairs, 
cells)
Unperturbed 1.15 ± 0.52 196, 12 0.10 ± 0.07 80, 12 P < 0.01
Taxol 0.87 ± 0.43 188, 12 0.08 ± 0.06 174, 12 P < 0.01
Nocodazole 0.88 ± 0.45 162, 12 0.92 ± 0.44 193, 12 P = 0.76
Mean fluorescence intensity values are normalized to CENP-A staining, and n represents the number of kinetochore pairs quantified followed by the number of cells 
analyzed. The p-values were calculated using the Student’s t test.JCB • VOLUME 195 • NUMBER 3 • 2011   454
Figure 3.  Chk1 is required for Ser331 phosphorylation in the presence of taxol. (A and B) BE cells transfected with negative siRNA (control) or Chk1 
siRNA (siChk1) were treated with taxol (A) or nocodazole (B) for 4 h. The frequency of cells exhibiting the respective phenotype and mean pS331/CENP-A 
fluorescence intensity values (boxed numbers) are shown. (C) Localization of total Aurora B. BE cells were transfected as in A and treated with taxol 
or nocodazole for 4 h. (D) Western blot analysis of 6×Myc–Aurora B (Myc) and actin in CHO
WT and CHO
S331A cells after induction with tetracycline.   
(E and F) Localization of 6×Myc–Aurora B proteins. Tetracycline-induced CHO
WT or CHO
S331A cells were untreated (E) or treated with taxol or nocodazole 
(F) for 4 h. Insets show magnified kinetochores. Bars, 5 µm.455 Chk1 phosphorylates Aurora B at serine 331 • Petsalaki et al.
Figure 4.  Phosphorylation of Ser331 is required for complete Aurora B activation. (A) Phosphorylation of Ser331 (pS331) during unperturbed prometa-
phase. CHO
WT and CHO
S331A cells expressing CENP-A–GFP were induced with tetracycline. (B) Immunoprecipitation kinase assay. CHO
WT and CHO
S331A 
cells induced with tetracycline were untreated (un) or treated with nocodazole (nocod) or taxol for 8 h in the absence or presence of VX-680. (top) Western 
blot analysis of Myc-associated phosphorylation of Ser10 of histone H3 (pH3). (bottom) Western blot of immunoprecipitated (IP) Myc. (C) Densitometric 
analysis of pH3 levels from B. pH3 levels in sample 1 were arbitrarily set to 1. Error bars show the standard deviation from the mean from three indepen-
dent experiments. The p-values were calculated using the Student’s t test. (D) Mitotic index of each sample from B at the time of harvesting (untreated or 
shake-off cells). (E) In vitro kinase assay. Complexes of purified Chk1, Aurora B, and GST-INCENP
826–919 were incubated with histone H3, and pH3 (top) 
or pS331 activities (bottom) were determined. Values show the relative levels of pH3 or pS331, and levels at 0 min were arbitrarily set to 1. Western 
blot analysis of total H3 and Aurora B is also shown. Black lines indicate that intervening lanes have been spliced out. (F) Coimmunoprecipitation assay. 
(top) Western blot analysis of immunoprecipitated (IP) 6×Myc–Aurora B (Myc) and V5-INCENP (V5) after induction of CHO
WT and CHO
S331A cells with 
tetracycline. (bottom) Western blot analysis of total Myc, V5, and actin. (G) Phosphorylation of Thr232 (pT232). CHO
WT and CHO
S331A cells were induced 
with tetracycline and treated with taxol for 4 h. The frequency of cells exhibiting the respective phenotype and mean pT232/CENP-B fluorescence intensity 
values (boxed numbers) are shown. Insets show magnified kinetochores. WT, wild type. Bars, 5 µm.JCB • VOLUME 195 • NUMBER 3 • 2011   456
Figure 5.  Phosphorylation of Ser331 is required for TSS phosphorylation. (A) Localization of INCENP-GFP. (top) CHO
WT cells expressing INCENP-
GFP were induced with tetracycline. (bottom) BE cells expressing INCENP-GFP. (B and C) Phosphorylation of INCENP at Ser850 (pS850). CHO
WT and 
CHO
S331A cells expressing INCENP-GFP were induced with tetracycline and treated with taxol (B) or nocodazole (nocod, C) for 4 h. The frequency of cells 457 Chk1 phosphorylates Aurora B at serine 331 • Petsalaki et al.
mitotic cells were selectively isolated by shake off or left 
untreated and harvested without shake off. Cell extracts were 
analyzed for Myc­associated kinase activity against histone 
H3 serine 10, a physiological substrate of Aurora B, by immuno­
precipitation kinase assays (Adams et al., 2001). As shown in 
Fig. 4 B and quantified in Fig. 4 C, treatment with taxol or 
nocodazole induced H3 serine 10 phosphorylation (pH3) com­
pared with untreated cells. However, pH3 activity was de­
creased in CHO
S331A compared with CHO
WT cells (Fig. 4,   
B and C) despite similar mitotic indices in the respective samples 
(untreated or shake­off cells) in both cell lines (Fig. 4 D). In 
comparison, VX­680 almost completely inhibited pH3 activity 
(Fig. 4, B and C).
Furthermore, we analyzed the ability of Chk1 to enhance 
Aurora B catalytic activity, indicated by pH3, in vitro (Zachos 
et al., 2007). Chk1 stimulated pH3 activity in the presence or 
absence of GST­INCENP
826–919, and this coincided with Aurora B 
phosphorylation at Ser331 (Figs. 4 E and S3 A). Collectively, 
these results suggest that Ser331 phosphorylation is required 
for optimal Aurora B activation. Mutation of Ser331 to aspar­
tate did not restore Aurora B kinase activity in immunoprecipi­
tation kinase assays, thus suggesting that this mutation doesn’t 
effectively mimic Ser331 phosphorylation in this case (unpub­
lished data).
Ser331 phosphorylation is not essential 
for Aurora B binding to INCENP or  
Thr232 phosphorylation
Binding to INCENP and phosphorylation at Thr232 stimulate 
Aurora B activity. To investigate the significance of Ser331 
phosphorylation for Aurora B association with INCENP, CHO
WT, 
or  CHO
S331A,  cells  transiently  expressing  V5­tagged  human   
INCENP were induced with tetracycline, V5­INCENP was pre­
cipitated from cell extracts using an antibody against V5, and asso­
ciated 6×Myc–Aurora B was detected by Western blotting against 
Myc. As shown in Fig. 4 F, similar levels of wild­type or S331A 
Aurora B precipitated with wild­type V5­INCENP
WT or mutant 
V5­INCENP
3A, in which the TSS motif was changed to AAA 
(Honda et al., 2003). In comparison, 6×Myc–Aurora B proteins 
did not associate with truncated V5­INCENP
1–787 lacking the   
C­terminal segment for binding to Aurora B (Fig. 4 F). Further­
more, similar levels of wild­type or S331A Aurora B precipi­
tated with V5­INCENP
WT after treatment of cells with taxol or 
nocodazole (Fig. S3 B). These results suggest that phosphory­
lation at Ser331 is not required for Aurora B association   
with INCENP.
Furthermore, CHO cells expressing wild­type or S331A 
Aurora B exhibited similar levels of phospho­Thr232 (pT232) 
Aurora B at centromeres in the presence of taxol (Fig. 4 G and 
Table S1) or nocodazole (Fig. S3 C and Table S1) as deter­
mined by pT232/CENP­B fluorescence intensity levels. Col­
lectively, these results suggest that phosphorylation at Ser331 
is not required for Aurora B binding to INCENP or phosphory­
lation at Thr232.
Ser331 phosphorylation is required for 
INCENP phosphorylation at TSS residues
Phosphorylation of the TSS motif is required for full Aurora B 
activation. To investigate phosphorylation at TSS residues, 
CHO
WT, CHO
S331A, or BE cells transiently expressing Xenopus 
laevis INCENP fused to GFP (INCENP­GFP) were examined 
for  phosphorylation  at  Ser850  (pS850)  inside  the  Xenopus 
TSS motif by confocal microscopy (Knowlton et al., 2006).   
INCENP­GFP colocalized with 6×Myc–Aurora B in CHO
WT 
and CHO
S331A cells and also with endogenous Aurora B in BE 
cells (Fig. 5 A and not depicted).
After induction with tetracycline and treatment with taxol 
or  nocodazole,  CHO
WT  prometaphase  cells  exhibited  pS850 
staining, and pS850 partially colocalized with INCENP­GFP 
near kinetochores (Fig. 5, B and C). In contrast, CHO
S331A cells 
exhibited diminished pS850 staining compared with controls   
as shown by pS850/INCENP­GFP fluorescence intensity (Fig. 5,   
B and C; and Table II).
Furthermore,  BE  cells  expressing  INCENP­GFP  and 
treated with UCN­01 exhibited reduced pS850 staining com­
pared with controls in the presence of taxol (Fig. S3 D and 
Table S1). Remarkably, in the presence of nocodazole, both 
control and UCN­01–treated BE cells exhibited similar levels 
of pS850 staining (Fig. S3 E and Table S1), and this is consis­
tent with Chk1 being required for Ser331 phosphorylation in 
exhibiting the respective phenotype and mean pS850/INCENP-GFP fluorescence intensity values (boxed numbers) are shown. (D) Immunoprecipitation   
kinase assay. CHO
WT and CHO
S331A cells expressing V5-INCENP were induced with tetracycline and treated with taxol for 8 h. (top) Western blot analysis of 
V5-associated phosphorylation of Ser10 of histone H3 (pH3). (middle and bottom) Western blot analysis of immunoprecipitated Myc and V5. Values show 
the relative pH3 and Myc levels with levels at sample 1 arbitrarily set to 1. (E) Densitometric analysis of pH3 levels from D. The p-values were calculated 
using the Student’s t test. (F) Mitotic index of each sample from D at the time of harvesting. Error bars show the standard deviation from the mean from three 
independent experiments. Insets show magnified kinetochores. WT, wild type. Bars, 5 µm.
 
Table II.  pS850 fluorescence intensity values at prometaphase kinetochores
Treatment CHO
WT cells CHO
S331A cells P-values
Fluorescence intensity  
(pS850/GFP)
n (kinetochore pairs, 
cells)
Fluorescence intensity  
(pS850/GFP)
n (kinetochore pairs, cells)
Taxol 0.81 ± 0.19 89, 10 0.18 ± 0.11 81, 10 P < 0.01
Nocodazole 0.88 ± 0.33 88, 11 0.12 ± 0.10 74, 10 P < 0.01
Mean fluorescence intensity values are normalized to GFP staining, and n represents the number of kinetochore pairs quantified followed by the number of cells 
analyzed. The p-values were calculated using the Student’s t test.JCB • VOLUME 195 • NUMBER 3 • 2011   458
Figure 6.  Expression of S331A Aurora B correlates with chromosome missegregation and impaired accumulation of BubR1 at kinetochores. (A–E) CHO
WT 
and CHO
S331A cells were induced with tetracycline. (A) Missegregated chromosomes are indicated by arrows. (B) Micronuclei are indicated by arrows.   
A single image plane is shown. (C) Localization of BubR1. The frequency of cells exhibiting the respective phenotype and mean BubR1/CENP-B fluorescence 459 Chk1 phosphorylates Aurora B at serine 331 • Petsalaki et al.
the presence of taxol but not nocodazole. Collectively, these 
results suggest that phosphorylation at Ser331 is required for 
optimal phosphorylation of INCENP at TSS residues.
Phosphorylations at Ser331 and TSS 
stimulate complete Aurora B activation
To further investigate the mechanism of Aurora B activation, 
CHO
WT or CHO
S331A cells transiently expressing V5­INCENP 
were treated with tetracycline and taxol, mitotic cells were se­
lectively isolated by shake off, and V5­associated pH3 activ­
ity was determined by immunoprecipitation kinase assay. As 
shown in Fig. 5 D and quantified in Fig. 5 E, cells expressing 
6×Myc–Aurora B
WT/V5­INCENP
3A or 6×Myc–Aurora B
S331A/
V5­INCENP
WT exhibited reduced levels of pH3 activity com­
pared with those expressing the wild­type complex despite sim­
ilar mitotic indices in shake­off cells in all samples (Fig. 5 F).   
Significantly, mutation of both Ser331 and TSS to alanine did 
not further reduce pH3 activity (Fig. 5, D and E), and this is 
consistent with Ser331 being required for TSS phosphoryla­
tion. In comparison, V5­associated pH3 activity was almost un­
detectable in cells expressing truncated V5­INCENP
1–787 (Fig. 5, 
D and E). These results show that phosphorylations at Ser331 
and TSS are required for complete Aurora B activation.
Expression of S331A Aurora B 
correlates with spontaneous chromosome 
missegregation, impaired accumulation  
of BubR1 at kinetochores,  
and cell multinucleation
Reduced Aurora B activity is associated with defects in chro­
mosome alignment, segregation, and cytokinesis. Microscopic 
examination  of  CHO
S331A  cells  after  induction  with  tetra­
cycline revealed that 20/50 (40%) of metaphases exhibited mis­
aligned chromatin (Fig. S4 A), and 23/50 (46%) of anaphases 
showed  one  or  few  missegregated  chromosomes  (Fig.  6  A) 
compared with only 5/50 (10%) and 4/50 (8%), respectively, in 
CHO
WT cells. Missegregated chromosomes can give rise to 
micronuclei (Gisselsson, 2008). After induction with tetracycline 
for 16 h, 26/136 (19%) of CHO
S331A cells in interphase exhib­
ited  one  or  few  micronuclei  compared  with  4/121  (3%)  of 
CHO
WT cells (Fig. 6 B).
Furthermore,  CHO
S331A  cells  induced  with  tetracycline 
exhibited impaired accumulation of BubR1 at prometaphase   
kinetochores  as  shown  by  reduced  BubR1/CENP­B  fluores­
cence intensity compared with controls (Fig. 6 C and Table S1). 
However, BubR1 levels per se were not diminished by over­
expression of Aurora B transgenes (Fig. 6 D).
Incomplete cytokinesis can cause bi­ or multinucleation 
(Xu et al., 2010). In the presence of tetracycline, CHO
S331A cells 
exhibit a rapid increase in the bi/multinucleation index com­
pared with CHO
WT cells (Figs. 6 E and S4 B). Collectively, these 
results suggest that phosphorylation of Aurora B at Ser331 is 
required for optimal chromosome alignment and segregation, 
accumulation of BubR1 at kinetochores, and successful cyto­
kinesis in the absence of spindle poisons.
Phosphorylation of Ser331 is required 
for sustained mitotic delay and BubR1 
maintenance to kinetochores in the 
presence of taxol
Furthermore, treatment with tetracycline and taxol induced 
accumulation of CHO
WT cells in mitosis as determined by micro­
scopic examination of condensed chromatin (Fig. 6 F). In 
contrast, although the proportion of mitotic cells in CHO
S331A 
cultures treated with taxol initially increased, this increase was 
not sustained, and the mitotic index was significantly reduced 
after 8–12 h compared with CHO
WT cells (Fig. 6 F). Impor­
tantly,  CHO
WT  and  CHO
S331A  cells  treated  with  tetracycline 
and nocodazole accumulated in mitosis with similar kinetics   
(Fig. 6 G). Also, after prolonged treatment with taxol, 30% 
of CHO
S331A cells accumulated DNA content greater than 4N as 
determined by flow cytometry (Fig. 6 H).
After treatment with taxol for 4 h, CHO
S331A cells ex­
hibit reduced staining of BubR1 at kinetochores by approxi­
mately ninefold compared with CHO
WT cells as determined by 
BubR1/CENP­B fluorescence intensity (Fig. 7 A and Table S1). 
In contrast, after treatment with nocodazole for 4 h, CHO
WT 
and CHO
S331A cells exhibit similar levels of BubR1 staining at 
kinetochores (Fig. 7 B and Table S1), therefore showing that 
kinetochores in CHO
S331A cells are capable of BubR1 binding. 
Importantly, after treatment with taxol for 1 h, BubR1 was read­
ily detectable at kinetochores in CHO
S331A cells, and BubR1/
CENP­B fluorescence intensity was reduced by only 1.3­fold 
compared with CHO
WT cells (P = 0.036; Fig. 7 C and Table S1). 
These results show that BubR1 is recruited to kinetochores 
in CHO
S331A cells in the presence of taxol and that it is BubR1 
maintenance at kinetochores rather than its initial recruitment 
that is affected in CHO
S331A cells. Collectively, these results 
suggest that phosphorylation of Aurora B at Ser331 is required 
for sustained mitotic delay and BubR1 maintenance at kineto­
chores in the presence of taxol.
Inhibition of Mps1 does not further reduce 
Aurora B activity in Chk1-depleted cells
Mps1 enhances Aurora B activity. Depletion of Chk1 by siRNA 
or inhibition of Mps1 activity by AZ3146 in BE cells treated 
with  taxol  diminished  Aurora  B  kinase  activity  by  approxi­
mately threefold (P < 0.001) and 1.9­fold (P < 0.001), respec­
tively, compared with controls, as indicated by lower levels of 
phosphorylated serine 7 (pS7) of CENP­A (Fig. 7 D and Table 
S1; Zeitlin et al., 2001; Hewitt et al., 2010). Significantly, 
treatment of Chk1­depleted cells with AZ3146 did not further 
intensity values (boxed numbers) are shown. Insets show magnified kinetochores. (D) Western blot analysis of BubR1 and actin. (E) Bi/multinucleation 
indices of interphase cells. A minimum of 300 cells per sample from one experiment was analyzed. TC, tetracycline. (F and G) Mitotic index analysis of 
CHO
WT and CHO
S331A cells after induction with tetracycline and treatment with taxol (F) or nocodazole (G). (H) Polyploidy in CHO
S331A cells. CHO
WT and 
CHO
S331A cells were treated with tetracycline and taxol, and DNA content greater than 4N was determined. Error bars show the standard deviation from 
the mean from three experiments. Bars, 5 µm.
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Figure 7.  Cells expressing S331A Aurora B exhibit unstable binding of BubR1 to kinetochores in response to taxol. (A–C) Localization of BubR1. CHO
WT 
and CHO
S331A cells were induced with tetracycline and treated with taxol (A and C) or nocodazole (nocod, B) for the indicated times. The frequency of 
cells exhibiting the respective phenotype and mean BubR1/CENP-B fluorescence intensity values (boxed numbers) are shown. (D) Phosphorylation of Ser7 
of CENP-A (pS7). BE cells transfected with negative siRNA (control) or Chk1 siRNA (siChk1) were treated with taxol for 4 h in the absence or presence 
of AZ3146 (AZ) or VX-680 (VX). The frequency of cells exhibiting the respective phenotype and mean pS7/CENP-A fluorescence intensity values (boxed 
numbers) are shown. Insets show magnified kinetochores. Bars, 5 µm.461 Chk1 phosphorylates Aurora B at serine 331 • Petsalaki et al.
et al., 2003). Furthermore, CHO
S331A cells exhibit multinu­
cleation and phenocopy DT40 cells expressing TAA mutant   
INCENP, which is consistent with Ser331 being required for   
TSS phosphorylation (Xu et al., 2010). In addition, overexpression 
of Aurora B
S331A impaired mitotic delay and BubR1 maintenance 
to kinetochores during treatment of cells with taxol. However,   
it did not diminish mitotic accumulation induced by nocodazole. 
It is possible that low Aurora B activity in cells expressing 
Aurora  B
S331A  is  sufficient  for  spindle  checkpoint  response 
when  microtubules  are  absent,  whereas  phosphorylation  at 
Ser331 and higher levels of kinase activity are required for   
a robust response against taxol (Xu et al., 2009; Santaguida 
et al., 2011).
Combining inhibition of Mps1 with Chk1 depletion did 
not exhibit an additive effect on Aurora B activity, thus sug­
gesting that Mps1 and Chk1 are involved in the same step of 
Aurora B activation. Mps1 phosphorylates Borealin to enhance 
Aurora B activity (Jelluma et al., 2008; Sliedrecht et al., 2010). 
One possibility is that phosphorylation of Borealin by Mps1 facil­
itates Ser331 or TSS phosphorylation, for example by stabiliz­
ing interactions between CPC proteins (Vader et al., 2006). 
Clarifying how Borealin contributes to stimulation of Aurora B 
activity is required to test this idea.
CHO
S331A exhibits lower levels of Survivin associated with 
the CPC compared with CHO
WT cells. Because Survivin binds 
to the CPC as a monomer, we propose that Survivin association 
with the partially active complex is weaker compared with the fully 
active complex (Jeyaprakash et al., 2007). Furthermore, depletion 
of Survivin reduced accumulation of wild­type and S331A 
Aurora B to centromeres, consistent with a role for Survivin in 
mediating targeting of the CPC to chromosomes (Vader et al., 
2006; Kelly et al., 2010). Our preliminary results suggest that 
depletion of Survivin in CHO
S331A cells further impairs the check­
point response to taxol by reducing localization of Aurora B
S331A  
to centromeres, thus further diminishing Aurora B activity at   
centromeres and kinetochores.
On the basis of those findings, we propose the following 
model for Aurora B activation (Fig. 8 E). Aurora B associated 
with INCENP and Survivin is autophosphorylated at Thr232 
and  partially  active.  During  unperturbed  prometaphase  or 
treatment of cells with taxol, Chk1 phosphorylates Aurora B 
at Ser331, and this phosphorylation is required for phosphory­
lation of INCENP at the TSS motif and complete kinase acti­
vation. In contrast, cells in prophase, anaphase, and cytokinesis 
or treated with nocodazole, can phosphorylate Ser331 through 
an unidentified kinase (Fig. 8 E, question mark) and achieve 
full Aurora B activity independently of Chk1. Furthermore, 
Survivin binding to the CPC is stronger in the fully active 
compared with the partially active complex, and Mps1 con­
tributes to full Aurora B activation, presumably by phosphory­
lating Borealin (for simplicity not depicted in the complex). 
Our model raises several important questions regarding the 
significance of Ser331 phosphorylation for Aurora B protein 
conformation, the role of this phosphorylation in modulating 
Survivin association with the CPC, and the potential role of 
protein phosphatases and kinases in regulating phosphory­
lation of Ser331.
reduce Aurora B activity (Fig. 7 D). In comparison, VX­680 
further diminished Aurora B activity in Chk1­depleted cells by 
approximately fourfold (P < 0.001; Fig. 7 D). These results 
show that combining inhibition of Mps1 with Chk1 depletion 
does not exhibit an additive effect on Aurora B activity.
Phosphorylation of Ser331 is required for 
optimal Survivin association with the CPC
The phenotype described for CHO
S331A cells is similar to the 
phenotype reported after depletion of Survivin in human cells 
(Carvalho et al., 2003). As shown in Fig. 8 (A and B), Survivin 
associated with 6×Myc–Aurora B was reduced in CHO
S331A 
compared with CHO
WT cells after treatment with tetracycline 
and taxol. However, Survivin­GFP localized to centromeres in 
all CHO
WT (20/20) and CHO
S331A (25/25) cells transiently ex­
pressing Survivin­GFP in the presence of taxol (Fig. 8 C). These 
results suggest that Ser331 phosphorylation is required for opti­
mal association of Survivin with the CPC but not for Survivin 
localization to centromeres. Furthermore, depletion of Survivin 
by  siRNA  (Fig.  S4  C,  siSurvivin)  reduced  accumulation  of 
wild­type or S331A 6×Myc–Aurora B to centromeres compared 
with controls (Figs. 8 D and S4 D).
Discussion
Complete  Aurora  B  activation  occurs  through  a  two­step 
mechanism: in the first step, Aurora B binds to INCENP and 
is partially activated, and in the second step, Aurora B phos­
phorylates INCENP at the TSS motif and becomes fully active 
(Bishop and Schumacher, 2002). In the present study, we show 
that human Aurora B is phosphorylated at the conserved residue 
Ser331 during unperturbed mitosis or treatment of cells with 
spindle poisons. Aurora B phosphorylated at Ser331 localizes 
to kinetochores in prometaphase, the midzone in anaphase, and 
the midbody in telophase and cytokinesis. Chk1 is required for 
Ser331 phosphorylation during unperturbed prometaphase or 
treatment of cells with taxol, a drug that stabilizes microtubules 
and primarily interferes with tension at kinetochores; however, 
Chk1 is dispensable for Ser331 phosphorylation during pro­
phase, cytokinesis, or complete microtubule depolymerization 
by nocodazole. To our knowledge, this is the first non–T­loop 
phosphorylation reported for Aurora B, and Chk1 is the first 
kinase known to phosphorylate Aurora B (Yasui et al., 2004).
To investigate the significance of Ser331 phosphory­
lation, we generated CHO cells expressing wild­type or S331A 
Aurora B, in which Ser331 was mutated to alanine, under con­
trol of a tetracycline­induced promoter. Using the aforemen­
tioned cell lines, we proposed that phosphorylation at Ser331 is 
required for efficient phosphorylation of INCENP at TSS resi­
dues and complete Aurora B activation (Honda et al., 2003). 
However, it is not essential for Aurora B localization to cen­
tromeres, autophosphorylation at Thr232, or association with   
INCENP (Yasui et al., 2004; Rosasco­Nitcher et al., 2008).
In agreement with previous findings, reduced Aurora B 
activity in CHO
S331A cells correlates with chromosome misseg­
regation and impaired accumulation of BubR1 at kinetochores 
during unperturbed mitosis (Kaitna et al., 2000; Ditchfield   JCB • VOLUME 195 • NUMBER 3 • 2011   462
Figure 8.  Expression of S331A Aurora B correlates with reduced association of Survivin with the CPC. (A) Coimmunoprecipitation assay. CHO
WT and 
CHO
S331A cells were induced with tetracycline and treated with taxol for 4 h. (top and middle) Western blot analysis of immunoprecipitated (IP) Survivin 
and 6×Myc–Aurora B (Myc). Values show the relative levels of Survivin and Myc with levels at CHO
WT cells set to 1. (bottom) Western blot (WB) analysis 
of total Survivin, Myc, and actin. (B) Densitometric analysis of immunoprecipitated Survivin and Myc levels from A. Error bars show the standard deviation 
from the mean from three independent experiments. (C) Localization of Survivin-GFP. CHO
WT and CHO
S331A cells expressing Survivin-GFP were treated as 
in A. (D) Localization of 6×Myc–Aurora B (Myc). CHO
S331A cells were transfected with control or Survivin siRNA (siSurvivin), induced with tetracycline, and 
treated with taxol for 4 h. The frequency of cells exhibiting the respective phenotype and mean Myc/CENP-B fluorescence intensity values (boxed numbers) 
are shown. (E) Model for Aurora B (AurB) activation (see Discussion for details). P, phosphorylation; S, Survivin; question mark shows an unidentified 
kinase. Insets show magnified kinetochores. Bars, 5 µm.463 Chk1 phosphorylates Aurora B at serine 331 • Petsalaki et al.
Materials and methods
Antibodies and peptides
Anti-pS331 antiserum was generated in rabbits by immunization against 
the phosphorylated peptide pS331 (H2N-CPWVRANS[PO3H2]RRVLPPS-
CONH2) of human Aurora B (Eurogentec). The unphosphorylated peptide 
S331  (H2N-CPWVRANSRRVLPPS-CONH2)  was  used  in  competition 
experiments as appropriate.
Monoclonal antibodies against Chk1 (G-4), Myc (9E10), and Sur-
vivin (D-8) and polyclonal antibodies against CENP-B and pH3 were ob-
tained from Santa Cruz Biotechnology, Inc. Monoclonal antibodies against 
-tubulin (DM1A), -tubulin (GTU-88), and actin (AC-40) were obtained 
from Sigma-Aldrich. Monoclonal antibody to CENP-A (3–19) and poly-
clonal antibodies against human Aurora B (ab2254) and murine BubR1 
(ab28193) were obtained from Abcam. Monoclonal (AIM-1) antibody to 
Aurora B was purchased from BD, polyclonal antibody against V5 (ab3792) 
was purchased from Millipore, polyclonal phospho–CENP-A (Ser7) anti-
body was purchased from Cell Signaling Technology, and polyclonal anti-
body against histone H3 (pan) was obtained from Millipore. Monoclonal 
antibody against pT232 (pAB2.1) was a gift from M. Inagaki (Aichi Can-
cer Center Research Institute, Nagoya, Japan), and rabbit polyclonal anti-
serum against phosphorylated Ser850 of Xenopus INCENP was a gift from 
T. Stukenberg (University of Virginia, Charlottesville, VA).
Purified proteins
Recombinant proteins histone H1, histone H3, Chk1, GST-INCENP
826–916, 
kinase-active Aurora B, and Aurora B
KD (D200A) were obtained from Milli-
pore. Human Aurora B
WT, Aurora B
S331A, and Aurora B
T179A proteins were 
expressed in BL21 (DE3) cells (Agilent Technologies), purified using the 
6×His purification kit (B-PER; Thermo Fisher Scientific), and used as sub-
strates in kinase reactions.
Mutagenesis, cloning, and generation of cell lines
Human Aurora B cDNA was obtained by reverse transcription PCR by   
using total RNA from human fibroblasts. The PCR product was introduced 
as a EcoRI–NotI fragment into the pET-28a(+) vector (EMD) and completely 
sequenced. Point mutations T1052G (changing Ser331 to alanine) and 
A535G  (changing  Thr179  to  alanine)  were  generated  by  site-directed   
mutagenesis using the site-directed mutagenesis kit (QuikChange; Agilent 
Technologies).
To produce inducible CHO
WT and CHO
S331A cell lines, wild-type or 
T1052G Aurora B cDNAs were subcloned as EcoRI–NotI fragments into 
the 6×Myc-pcDNA3 vector (a gift from D. Kardassis, University of Crete, 
Heraklion, Greece), excised with BamHI–NotI, and introduced into the 
pcDNA5/FRT/TO  plasmid  (Invitrogen).  These  vectors  were  then  trans-
fected into CHO cells (T-REx; Invitrogen) stably expressing the tetracycline 
repressor together with the pTK-Hyg selection vector (Agilent Technologies) 
conferring resistance to hygromycin (Invitrogen).
To generate the V5-INCENP
WT and V5-INCENP
3A expression plas-
mids, human INCENP cDNA was excised with BamHI–XhoI from RH100/
pBSK INCENP or RH100/pBSK INCENP (TSS-AAA) plasmids, respectively 
(gifts from E. Nigg, Biozentrum, University of Basel, Basel, Switzerland), 
and cloned into the pcDNA3.1/V5-His vector (Invitrogen). Truncated   
V5-INCENP
1–787 was amplified by PCR from the RH100/pBSK INCENP plas-
mid and cloned as a BamHI–XhoI fragment into the pcDNA3.1/V5-His vector.
Plasmid pCS2+ GFP INCENP coding GFP fused to Xenopus INCENP 
was  obtained  from  T.  Stukenberg  (Knowlton  et  al.,  2006).  Plasmid 
CENP-A–GFP coding for human CENP-A fused to GFP in the pBos vector 
was obtained from K. Sullivan (Centre for Chromosome Biology, University 
of Ireland, Galway, Ireland; Kanda et al., 1998), and human Survivin-GFP 
plasmid was obtained from W. Earnshaw (Wellcome Centre for Cell 
Biology, University of Edinburgh, Edinburgh, Scotland, UK; Wheatley 
et al., 2001).
Cell culture, treatments, and RNA interference
Human colon carcinoma BE cells were grown in DME (Invitrogen) containing 
10% fetal bovine serum and CHO cells (T-REx CHO) in Ham’s F12 (Invitrogen) 
supplemented with 10% fetal bovine serum. All cells were cultured at 37°C 
and 5% CO2.
Cells were treated with 1 µg/ml nocodazole (Sigma-Aldrich), 1 µM 
taxol (Sigma-Aldrich), 3 µM VX-680 (Kava Technology, Inc.), or 2 µM 
AZ3146 (Axon) as appropriate. To induce expression of Aurora B trans-
genes, CHO
WT or CHO
S331A cells were treated with 17 or 30 ng/ml tetra-
cycline (Sigma-Aldrich), respectively, for 16 h before analysis or further 
treatment with drugs.
Serine 331 is at the foot of the Aurora B C­terminal tail 
inside a sequence essential for Aurora B activation (Scrittori   
et al., 2005). Phosphorylation of Ser331 may trigger release of 
the Aurora B C­terminal tail, phosphorylation of the TSS   
sequence, and complete Aurora B activation. Alternatively, 
phosphorylation of Aurora B at Ser331 may change INCENP 
conformation through an allosteric mechanism to make TSS 
residues more accessible to Aurora B, and the release of the 
C­terminal tail may be a consequence of TSS phosphorylation 
(Sessa et al., 2005). Crystallographic analysis of an Aurora B–
INCENP complex harboring phosphorylated Ser331 is re­
quired to distinguish between these possibilities.
Aurora  B  phosphorylates  Survivin  at  threonine  117 
(Thr117), and mutation of Thr117 to alanine prevented immuno­
precipitation  of  Survivin  with  INCENP  (Wheatley  et  al., 
2004, 2007). It is possible that Survivin is inefficiently phos­
phorylated at Thr117 in CHO
S331A compared with wild­type 
cells. Alternatively, phosphorylation at Ser331 may regulate 
Survivin association with the CPC indirectly, through changes 
in conformation of Aurora B–INCENP. Increased binding of 
Survivin to the fully active complex may facilitate interactions 
with Aurora B substrates and enhance Aurora B catalytic activ­
ity (Bolton et al., 2002).
Ser331 appears constitutively phosphorylated under all 
conditions examined. This is in agreement with a recent study 
showing that Aurora B activity does not significantly change 
during mitosis, based on phosphorylation of an artificial fluor­
escence resonance energy transfer probe substrate targeted to 
CENP­B (Liu et al., 2009). Furthermore, Aurora B phosphory­
lated at Ser331 localizes to kinetochores, where it is presum­
ably near its substrates. This is consistent with findings that 
active Aurora B efficiently promotes microtubule detachment if 
tethered within the kinetochore but not the centromere (Liu et al., 
2009) and also with a recent study showing a small population 
of pT232 Aurora B at kinetochores (Posch et al., 2010). Inter­
estingly, pS331 and pT232 proteins are only detectable at   
kinetochores under conditions that inhibit protein phospha­
tase activity (Gorbsky and Ricketts, 1993; Posch et al., 2010). 
Protein phosphatases are known to oppose Aurora B–mediated 
signaling (Emanuele et al., 2008; Meadows et al., 2011), and 
Sds22, a conserved regulator of Protein Phosphatase 1, was re­
cently shown to regulate Aurora B activity (Posch et al., 2010). 
Identifying phosphatases that reverse Ser331 phosphorylation 
and reduce Aurora B kinase activity will provide new insight 
into mechanisms that silence the spindle checkpoint (Meadows 
et al., 2011; Rosenberg et al., 2011).
In the absence of Chk1, other kinases mediate Ser331 
phosphorylation during prophase, cytokinesis, or treatment of 
cells with nocodazole. Phosphorylation of Ser331 by as yet un­
identified kinases may accelerate phosphorylated group forma­
tion when increased counteracting protein phosphatase activity 
has to be overcome, for example, during assembly of the outer 
kinetochore in prophase, or when Aurora B regulates large scale 
events, such as formation of the cleavage furrow in cytokinesis 
(Emanuele et al., 2008; Fuller et al., 2008). Identifying the full 
panel of Ser331 kinases will improve our understanding of how 
CPC functions are controlled in mitosis.JCB • VOLUME 195 • NUMBER 3 • 2011   464
Negative siRNA or siRNA duplexes designed to repress human 
Chk1 (Thermo Fisher Scientific), human Aurora B (Thermo Fisher Scien-
tific), or rat Survivin (QIAGEN) was transfected into BE or CHO cells 
48 h (siChk1), 24 h (Aurora B siRNA), or 72 h (Survivin siRNA) before 
analysis or treatment with drugs using Lipofectamine 2000 (Invitrogen). 
For transient expression of V5-INCENP or GFP proteins, plasmids were 
transfected into cells 24 h before analysis or treatment with drugs using 
Lipofectamine 2000.
Immunoprecipitations and kinase assays
For Myc immunoprecipitations shown in Fig. 8 A, cells were incubated in 
ice-cold E1A buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 0.1% NP-40,   
5 mM EDTA, 1 mM PMSF, 1 mM NaF, 10 µg/ml leupeptin, 10 µg/ml apro-
tinin, 30 µg/ml RNase, 10 mM sodium -glycerophosphate, 1 mM sodium 
vanadate, and 0.1 µM microcystin) for 30 min (Harlow et al., 1986).   
Approximately 1 mg cell lysate was incubated with 1 µg anti-Myc (9E10) anti-
body for 2 h followed by addition of 20 µl protein A/G PLUS–agarose 
beads (Invitrogen) for 16 h at 4°C. Samples were spun down, washed 
twice with E1A buffer, and analyzed by SDS-PAGE.
For the Myc immunoprecipitations shown in Fig. 4 B, cells were 
sonicated 3× for 10 s in ice-cold radioimmunoprecipitation buffer (50 mM   
Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1%   
SDS, 1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 30 µg/ml RNase, 
20  mM  sodium  -glycerophosphate,  and  0.3  mM  sodium  vanadate). 
0.3–1 mg cell lysate was incubated with 0.5 µg anti-Myc antibody for 
1 h followed by addition of 20 µl protein A/G PLUS–agarose beads for   
16 h at 4°C. Samples were spun down and washed twice with radio-
immunoprecipitation buffer, once with wash buffer (50 mM Tris-HCl,   
pH 8.0, 0.4 M NaCl, 1% NP-40, 0.5% deoxycholate, 1 mM PMSF, 1 µg/ml 
leupeptin, and 1 µg/ml aprotinin), and twice with Tris buffer (10 mM Tris-
HCl, pH 7.5, 150 mM NaCl, and 0.1 mM PMSF) essentially as previously 
described (Honda et al., 2003).
For V5 immunoprecipitations, cells were sonicated 3× for 10 s in ice-
cold immunoprecipitation buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 
1 mM EDTA, 2.5 mM EGTA, 0.1% Tween 20, 10% glycerol, 0.1 mM 
PMSF, 10 mM sodium -glycerophosphate, 0.1 mM Na3VO4, 1 mM NaF, 
10 µg/ml leupeptin, and 10 µg/ml aprotinin). 0.3–1 mg cell lysate was 
incubated with 0.5 µg anti-V5 antibody for 1 h followed by addition of 20 µl 
protein A/G PLUS–agarose beads for 16 h at 4°C. Samples were spun 
down, washed twice with immunoprecipitation buffer, and analyzed by 
SDS-PAGE (Figs. 4 F and S3 B) or included in kinase reactions (Fig. 5 D).
For Figs. 4 B and 5 D, immunoprecipitated proteins on agarose 
beads were included into a 20-µl reaction containing 1 µg histone H3,   
50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 5 mM 
NaF,  5  mM  sodium  -glycerophosphate,  50  µM  sodium  vanadate,  and   
0.1 mM ATP (Honda et al., 2003). For Figs. 4 E and S3 A, 0.2 µg recombi-
nant kinase-active Aurora B was included into a 20-µl reaction containing 
1 µg histone H3, 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 1 mM EGTA, 1 mM   
DTT, 5 mM NaF, 5 mM sodium -glycerophosphate, 50 µM sodium vana-
date, and 10 µM ATP. Where appropriate, 0.5 µg recombinant Chk1 
and/or 0.2 µg GST-INCENP
826–916 was included in the kinase reaction. 
Unless otherwise stated, reactions were incubated for 20 min at 30°C, 
stopped by addition of 2 µl 10× gel sample buffer, and analyzed by SDS-
PAGE and Western blotting using a polyclonal antibody against pH3.
For in vitro Chk1 kinase assays in Fig. 1, 0.5 µg recombinant Chk1 
was incubated with 1 µg protein substrate in 20 µl kinase buffer (20 mM 
MOPS, pH 7.2, 5 mM EGTA, 10 mM MgCl2, 25 mM sodium -glycero-
phosphate, 1 mM sodium vanadate, 1 mM DTT, 100 µM ATP, and 1 µCi 
-ATP) for 20 min at 30°C before analysis by SDS-PAGE. Radioactive   
labeling of Chk1 substrates was determined by autoradiography and densi-
tometric analysis of the bands (Zachos et al., 2007). Where appropriate, 
145 ng UCN-01 (Sigma-Aldrich) was included in the kinase reaction.
Indirect immunofluorescence microscopy
For pS331 staining, cells were rinsed twice in PHEM buffer (60 mM Pipes, 
25 mM Hepes, pH 7.0, 10 mM EGTA, and 4 mM MgSO4) extracted in 
PHEM supplemented with 0.5% CHAPS and 100 nM microcystin (Sigma-
Aldrich) for 5 min at room temperature, fixed with cold methanol for 5 min 
at 20°C, washed twice with PBS, and immunostained (Gorbsky and 
Ricketts, 1993). For all other fluorescence microscopy applications, cells 
were fixed in 4% paraformaldehyde in cytoskeleton buffer (1.1 M Na2HPO4, 
0.4 M KH2PO4, 137 mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM EGTA,   
5 mM Pipes, and 5 mM glucose, pH 6.1) for 5 min at 37°C, permeabi-
lized in 0.5% Triton X-100 in cytoskeleton buffer at room temperature, and 
immunostained as appropriate (Zachos et al., 2007).
FITC- or rhodamine-TRITC–conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories, Inc.) were used, DNA was stained with 
10 µM TO-PRO-3 iodide (642/661; Invitrogen), and cells were mounted 
in  VECTASHIELD  medium  (Vector  Laboratories).  Images  were  collected   
using a laser-scanning spectral confocal microscope (TCS SP2; Leica), LCS 
Lite software (Leica), and a 63× Apochromat 1.40 NA oil objective ex-
cept for Figs. 3 B, 6 (A and B), S1, S2, and S4 A, in which a 40× Apo-
chromat 1.25 NA oil objective was used. A low fluorescence immersion oil 
(11513859; Leica) was used, and imaging was performed at room tem-
perature. Unless otherwise stated, mean projections of image stacks were 
obtained using the LCS Lite software.
To analyze fluorescence intensities, background readings were sub-
tracted, and fluorescence intensities were quantified using LCS Lite. The 
pS331 values were normalized against the CENP-A signal, and the pS850 
was normalized against the GFP signal (also see Table S1). For Table I, 
four cells per experiment from three independent experiments were ana-
lyzed for each treatment. For Table II, three to four cells per experiment 
from three independent experiments were analyzed for each treatment. For 
Table S1, a minimum of three cells per experiment from at least two inde-
pendent experiments were analyzed for each treatment.
Mitotic and bi/multinucleation indices
Cells were fixed in 4% paraformaldehyde in cytoskeleton buffer, perme-
abilized in 0.5% Triton X-100, stained, and examined for condensed chro-
matin or bi/multinucleation by fluorescence microscopy. For Fig. 6 E,   
a minimum of 300 cells per sample was analyzed. For Fig. 6 (F and G),   
a minimum of 100 cells per sample was analyzed.
DNA content
Cells were fixed in 70% ethanol-PBS at 4°C, stained with 20 µg/ml pro-
pidium iodide in PBS (Sigma-Aldrich) and analyzed for DNA content by use 
of a flow cytometer (FACSan; BD).
Western blotting and densitometry
Cells were lysed in ice-cold whole-cell extract buffer (20 mM Hepes, 5 mM 
EDTA, 10 mM EGTA, 0.4 M KCl, 0.4% Triton X-100, 10% glycerol, 5 mM 
NaF, 50 ng/ml okadaic acid, 1 mM DTT, 5 µg/ml leupeptin, 50 µg/ml 
PMSF, 1 mM benzamidine, 5 µg/ml aprotinin, and 1 mM Na3VO4) for 
30 min on ice. Lysates were cleared by centrifugation at 15,000 g for 10 min. 
Densitometric analysis was performed using ImageJ (National Institutes   
of Health).
HPLC-Edman degradation
Radiolabeled Aurora B
KD was excised from an SDS-PAGE gel and digested 
with trypsin or glutamyl endopeptidase (ICN Pharmaceuticals, Inc.). Sam-
ples were acidified and loaded onto a C-18 column (Vydac) for HPLC   
essentially as previously described (Sanchez et al., 1997). Fractions were 
collected at 1-min intervals and counted for radioactivity, and selected 
fractions were immobilized on membrane discs for N-terminal sequencing 
(Sullivan and Wong, 1991).
Protein Data Bank image
The image of Xenopus Aurora B–INCENP
790–847 in complex with hespera-
dine (Sessa et al., 2005) was downloaded from the Protein Data Bank 
using Jmol (accession no. 2BFY).
Online supplemental material
Fig.  S1  shows  HPLC-Edman  analysis  of  radiolabeled  Aurora  B
KD  after 
digestion with glutamyl endopeptidase, Aurora B expression levels after 
treatment of BE cells with Aurora B siRNA, and specificity of the anti-pS331 
antiserum by immunofluorescence. Fig. S2 shows Chk1 and Aurora B ex-
pression levels after treatment of BE cells with Chk1 siRNA and Ser331 
phosphorylation in prophase and cytokinesis as well as Aurora B expres-
sion levels and Ser331 phosphorylation in CHO
WT and CHO
S331A cells.   
Fig. S3 shows Chk1 in vitro kinase assays, immunoprecipitation of 6×Myc–
Aurora B with V5-INCENP, Aurora B phosphorylation at Thr232, and   
INCENP phosphorylation at Ser850. Fig. S4 shows examples of CHO
WT 
and CHO
S331A cells in metaphase and interphase, expression of Survivin, and 
localization of 6×Myc–Aurora B after treatment of CHO
WT cells with Survivin 
siRNA. Table S1 shows fluorescence intensity values at prometaphase   
kinetochores after various treatments. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201104023/DC1.
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